

Amendments to Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A method for inhibiting proliferation or migration of ~~vascular~~ smooth muscle cells comprising treating said ~~vascular~~ smooth muscle cells with an effective amount of an antagonist antibody ~~antagonist~~ of a native ErbB4 receptor of SEQ ID NO.: 2.

2-9. (canceled)

10. (currently amended) The method of claim 1 wherein said ~~vascular~~ smooth muscle cells are human.

11. (currently amended) The method of claim 1 wherein said ~~vascular~~ smooth muscle cells are human aortic smooth muscle cells.

12-22. (canceled)

23. (previously presented) The method of claim 1 wherein said antibody is a neutralizing antibody against a native ErbB4 receptor of SEQ ID NO.: 2.

24. (original) The method of claim 23 wherein said antibody is a chimeric, humanized or human antibody.

25. (original) The method of claim 23 wherein said antibody is glycosylated.

26. (currently amended) A method for inhibiting proliferation or migration of ~~vascular~~ smooth muscle cells comprising treating said ~~vascular~~ smooth muscle cells with an effective amount of an antagonist antibody ~~antagonist~~ of a native ErbB4 receptor of SEQ ID NO.: 2 wherein said antibody ~~binds essentially the same~~ competes for binding to the epitope as bound by the an antibody produced by a hybridoma selected from the group consisting of HER4.10H1.1A1 (ATCC Accession Number PTA-2828), HER4.1C6.A11 (ATCC Accession Number PTA-2829), HER4.3B9.2C9 (ATCC

Accession Number PTA-2826), HER4.1A6.5B3 (ATCC Accession Number PTA-2827) and HER4.8B1.2H2 (ATCC Accession Number PTA-2825).

27. (currently amended) A method for inhibiting proliferation or migration of ~~vascular~~ smooth muscle cells comprising treating said ~~vascular~~ smooth muscle cells with an effective amount of an antagonist antibody ~~antagonist~~ of a native ErbB4 receptor of SEQ ID NO.: 2 wherein said antibody has complementarity determining region (CDR) residues having the amino acid sequence of a CDR amino acid sequence from an antibody produced by a hybridoma selected from the group consisting of HER4.10H1.1A1 (ATCC Accession Number PTA-2828), HER4.1C6.A11 (ATCC Accession Number PTA-2829), HER4.3B9.2C9 (ATCC Accession Number PTA-2826), HER4.1A6.5B3 (ATCC Accession Number PTA-2827) and HER4.8B1.2H2 (ATCC Accession Number PTA-2825).

28-84. (canceled)

85. (currently amended) The method of claim 27 wherein said ~~vascular~~ smooth muscle cells are human.

86. (currently amended) The method of claim 85 wherein said ~~vascular~~ smooth muscle cells are human aortic smooth muscle cells.

87. (previously presented) The method of claim 27 wherein said antibody is a neutralizing antibody against a native ErbB4 receptor of SEQ ID NO.: 2.

88. (previously presented) The method of claim 87 wherein said antibody is a chimeric, humanized or human antibody.

89. (previously presented) The method of claim 87 wherein said antibody is glycosylated.

90. (new) A method for inhibiting proliferation or migration of smooth muscle cells comprising treating said smooth muscle cells with an effective amount of an

antagonist antibody of a native ErbB4 receptor of SEQ ID NO.: 2 wherein said antagonist antibody is an antibody produced by a hybridoma selected from the group consisting of HER4.10H1.1A1 (ATCC Accession Number PTA-2828), HER4.1C6.A11 (ATCC Accession Number PTA-2829), HER4.3B9.2C9 (ATCC Accession Number PTA-2826), HER4.1A6.5B3 (ATCC Accession Number PTA-2827) and HER4.8B1.2H2 (ATCC Accession Number PTA-2825).

91. (new) The method of claim 90 wherein said smooth muscle cells are human.

92. (new) The method of claim 90, wherein said smooth muscle cells comprise vascular smooth muscle cells.

93. (new) The method of claim 91 wherein said smooth muscle cells are human aortic smooth muscle cells.